Sarepta Therapeutics presented topline results from Part 2 of Study SRP-9001-102 (Study 102), an ongoing phase 2 study evaluating a single dose of investigational gene…
Allogene Therapeutics announced the U.S FDA has removed the clinical hold on all the Company’s AlloCAR T clinical trials. In October of 2021, the FDA…
An eye condition known as inherited retinal degeneration can make even the most mundane tasks—like cooking, driving, and walking down the sidewalk—difficult or impossible, and…
On the TrialSite “PharmaWatch” radar are several companies involved with the research and development of potentially life-saving therapies, including Japan’s Astellas. Big pharmaceutical companies depend…
Holland-based biotech venture uniQure reports recently that its investigational gene therapy targeting Huntington’s disease known as AMT-130 was well-tolerated for up to one-year post-treatment in…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
